Teva Pharmaceutical Industries Aktie

30,30 EUR +0,50 EUR +1,68 %

04.05.2026

BMN

35,35 USD -0,03 USD -0,07 %

nachbörslich04.05.2026

BTT

Teva Pharmaceutical Industries jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

KGV25,54Div. Rendite0,00%

WKN883035

ISINUS8816242098

SymbolTEVA

Teva Pharmaceutical Industries Aktien News

Sortieren:Datum Meistgelesen

06.11.25PR NewswireTeva Canada Welcomes RAMQ Reimbursement Update Supporting Access to ADHD Treatments

03.06.25GlobeNewswireTeva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

03.06.25GlobeNewswireTeva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

WerbungTeva Pharmaceutical Industries-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

31.05.25GlobeNewswireNew Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

31.05.25GlobeNewswireTeva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New P

29.05.25GlobeNewswireTeva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

27.05.25GlobeNewswireTeva Celiac Disease Candidate Granted Fast Track Designation by US FDA

27.05.25GlobeNewswireTeva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

27.05.25GlobeNewswireTeva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

22.05.25GlobeNewswireTeva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

20.05.25GlobeNewswireTeva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

20.05.25GlobeNewswireFitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

19.05.25GlobeNewswireTeva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

19.05.25GlobeNewswireTeva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

16.05.25GlobeNewswireMoody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

12.05.25GlobeNewswireTeva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

07.05.25GlobeNewswireTeva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

05.05.25GlobeNewswireTeva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

07.04.25GlobeNewswireTeva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

07.04.25GlobeNewswireTeva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

31.03.25GlobeNewswireNew Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-

27.03.25GlobeNewswireTeva Releases Q1 2025 Aide Memoire

27.03.25GlobeNewswireTeva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

14.03.25PR NewswireTeva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma

03.03.25GlobeNewswireTeva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

27.02.25GlobeNewswire2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

25.02.25GlobeNewswireTeva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

22.02.25GlobeNewswireTeva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

21.02.25GlobeNewswireDer Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

21.02.25GlobeNewswireTeva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

18.02.25GlobeNewswireTeva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Orga

18.02.25GlobeNewswireAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

27.01.25GlobeNewswireAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

14.01.25GlobeNewswireTeva gibt Zusammenarbeit zur Vermarktung des Formycon Biosimilar-Kandidaten für Eylea® (Aflibercept) in großen Teilen Europas und in Israel bekannt

13.01.25GlobeNewswireTeva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

10.01.25GlobeNewswireSamsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

23.12.24GlobeNewswireTeva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

20.12.24GlobeNewswireTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

17.12.24GlobeNewswireTeva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

11.12.24GlobeNewswireTeva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva Pharmaceutical Industries News

Teva Pharmaceutical Industries News: auf dieser Seite finden Sie alle Teva Pharmaceutical Industries News und Nachrichten zur Teva Pharmaceutical Industries Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Teva Pharmaceutical Industries News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Teva Pharmaceutical Industries News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.